Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-07.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
Global varicella vaccination programs

Volume 65(12); December

< Previous     Next >

Article Contents

Clin Exp Pediatr > Volume 65(12); 2022
Lee, Choe, Lee, Kim, Lee, Hong, Yoon, and Kim: Global varicella vaccination programs


Varicella (chickenpox) is an infectious disease caused by the highly contagious varicella zoster virus with a secondary attack rate greater than 90%. From this perspective, we aimed to establish the basis for a national varicella vaccine policy by reviewing vaccination programs and policies of countries that have introduced universal varicella vaccinations. As a result of the spread of varicella, an increasing number of countries are providing 2-dose vaccinations and universally expanding their use. In practice, the efficacy and effectiveness of vaccination differ among vaccines and vaccination programs. Optimized vaccination strategies based on each country’s local epidemiology and health resources are required. Accordingly, it is necessary to evaluate the effectiveness of varicella vaccines in different settings. Given the short-term and fragmented vaccine effectiveness evaluation in Korea, it is necessary to evaluate its effectiveness at the national level and determine its schedule based on the evidence generated through these studies.

Graphical abstract


Varicella is a communicable disease caused by the highly contagious varicella zoster virus (VZV), with a secondary incidence of >90% in susceptible populations [1,2]. Varicella is generally considered a mild disease in healthy children, with symptoms such as an itchy rash, malaise, pruritus, and fever for 2–3 days. However, VZV becomes latent in the neural ganglia after the primary infection. The incubation period typically lasts a lifetime, and the virus can be reactivated as herpes zoster when one’s immunity declines [3,4].
Active immunization is an important preventive intervention for varicella, vaccines for which are reportedly effective at reducing its worldwide incidence and disease burden [5]. The World Health Organization (WHO) recommends introducing universal varicella vaccinations in countries in which varicella provides an important burden of disease under conditions that can ensure reaching and sustaining a high vaccine coverage of more than 80% [6].
For effective prevention of varicella, it is important to both maintain high vaccine coverage and have a strategic plan against vaccine failure. Vaccine failure can be classified as primary, referring to inadequate primary immune mounting, and secondary, generally caused by waning immunity over time [7]. A single-dose varicella vaccine may effectively reduce disease severity, but is prone to breakthrough infections [8-12]. A 2-dose varicella vaccine reduces the disease severity and the incidence of breakthrough cases [13-16]. Since the introduction of the varicella vaccine as a NIP in 2005, Korea has achieved a high vaccine coverage of 96.3% (as of 2019) [17]; however, breakthrough cases are still reported [18,19].
In 1995, the United States was the first country to adopt a 1-dose varicella vaccine as a universal program. Since then, countries that introduced the varicella vaccine as a universal program have evaluated its effectiveness through a study of disease burden [3,5,20-23]. However, some countries still have no universal varicella vaccine program for infants and selectively vaccinate only high-risk groups or healthcare workers [24]. This is because healthy children often develop mild symptoms when infected with varicella; hence, the urgency lags behind that of other new vaccines, including those for the human papilloma virus, rotavirus, and Streptococcus pneumoniae [24,25].
The consequences of the age shift of varicella cases to older age groups are also pushing back a universal varicella vaccination on the priority list. The reduction in varicella incidence in children reduces the chance of natural immune boosting in the elderly population, resulting in an increase in the incidence of herpes zoster infection. Moreover, the age shift in varicella infection may lead to a more severe disease [24,26]. Other factors such as cost-effectiveness of the vaccination program also influence public health priorities. Considering the health investment trade-offs, a country has 3 options to choose from regarding the national immunization schedule: no adoption, a 1-dose vaccination regimen to alleviate disease severity, or a 2-dose vaccination regimen to ultimately eradicate VZV.
Here we assess the rationale for vaccination programs to derive the necessary basis for domestic varicella vaccine policy by reviewing vaccination programs in different countries and describing their policy of introducing a universal varicella vaccination program.
We conducted a nonsystematic review to identify the countries in which the varicella vaccine was provided as a universal vaccination program. Countries providing the varicella vaccine as a universal vaccination program were investigated through the websites of the WHO and the European Center for Disease Prevention and Control. This comprehensive literature review aimed to obtain a complete record of all the available literature on varicella vaccination programs in different countries using the following PubMed search terms: country + varicella, vaccine, country + vaccination, country + schedule, country + vaccination program, country + universal vaccination, country + vaccine strain, and country + coverage. The countries were grouped into 6 regions according to WHO groupings: Western Pacific, Europe, America, Eastern Mediterranean, Africa, and Southeast Asia.
The varicella vaccine is a live attenuated vaccine. The Oka vaccine was developed in Japan in 1974, and the MAV vaccine, another live attenuated varicella vaccine, was developed in Korea in 1993 [27,28]. Except for 1 type of varicella vaccine based on the MAV strain, which is licensed in Korea, the Oka strain is used globally for varicella vaccines [29]. Currently licensed live attenuated vaccines include the monovalent varicella vaccine and measles, mumps, rubella and varicella (MMRV) vaccine, a tetravalent vaccine (Table 1). As of the first half of 2021, 44 countries have introduced the varicella vaccine as a universal vaccination for infants. However, the vaccination schedules vary in that some countries use a single dose, whereas other countries use a second dose (Table 2, Fig. 1). Overall, 28 countries use a universal 2-dose varicella vaccine regimen for infants; mandatory vaccinations are provided in all countries except Austria and Cyprus.

Varicella vaccination status by region

1. Western Pacific region

Only a few countries in the Western Pacific region have adopted a universal varicella vaccine regimen. Taiwan was the first country to introduce the varicella vaccine in 2004, followed by Australia and Korea in 2005. Among the countries that introduced a universal varicella vaccine, all but Hong Kong and Japan started a 1-dose vaccination; 17 years later, a high vaccination rate (>90%) was confirmed in Australia, Korea, and Taiwan [17,30,31]. In Japan, where the first varicella vaccine (Oka) was developed, a universal vaccination for infants was introduced in 2014, but the vaccination rate was low (about 40%) [32]. As of 2021, the varicella vaccine has been used in 7 Western Pacific countries, and the MMRV vaccine combined with the MMR vaccine has only been used in Hong Kong as a 2-dose regimen.
In Korea, the varicella vaccine was introduced in the private market in 1988, and it has been recommended as an option for high-risk groups and healthy children [7]. Since 2005, varicella vaccinations have been recommended as part of the national immunization program for all children aged 12–15 months. The varicella vaccine was an imported product until 1993 in Korea, after which time several varicella vaccines were developed by domestic companies. However, imported vaccines were also used. The varicella vaccines developed in Korea include Okabased vaccines such as Suduvaccine (CJ Cheil, Seoul, Korea), LG Suduvaccine (LG Chemical, Seoul, Korea), and the MAV-based Suduvax (GC Green Cross, Yongin, Korea) [7]. The varicella vaccines on the market in Korea as of the first half of 2021 are Oka-based, namely Vari-L (2,000 plague-forming units [PFU]; Changchun Institute of Biological Products, Jilin, China), SKY varicella (2,400 PFU; SK Bioscience, Seongnam, Korea), the MAV-based Suduvax (1,400 PFU; Green Cross), and varicella vaccine (3,800 PFU; Green Cross) (Table 1). Priorix-Tetra (GSK, London, UK), an MMRV vaccine, was approved by the Ministry of Food and Drug Safety in 2013, but it is not currently on the market.

2. European region

In Europe, varicella vaccines are used in 28 countries, of which 16 use MMRV vaccines [3]. As of 2021, varicella vaccination is recommended by the National Immunization Program (NIP) in 14 countries, 12 of which are conducting a universal vaccination program.
The first countries in Europe to adopt the varicella vaccine as a 1-dose vaccination schedule were Germany in 2004 and Greece in 2006; both countries began to administer a universal 2-dose schedule. In Germany, a 2-dose vaccination policy was adopted because of persistent community and individual-level breakthrough infections despite the introduction of a one-dose vaccination regimen [33]. In Greece, although the effectiveness of a 1-dose vaccination has not been evaluated because varicella is not a notifiable disease, a 2-dose vaccination regimen was introduced to enhance immunity [34].
Italy and Spain introduced universal vaccination programs by region and then expanded them country-wide. In Italy, Sicily first introduced a universal varicella vaccine regimen in 2003; Veneto introduced a 2-dose vaccination regimen in 2005 for children aged 14 months and 6 years; and Toscana started a 1-dose vaccination program in 2008 [35]. Since then, through its National Plan for Vaccination, Italy implemented a mandatory universal vaccination for infants nationwide in 2017 [36].
Spain introduced a 1-dose vaccination program for children at 15 months of age, and a catch-up vaccination was provided in November 2006 for children aged 10 years in Madrid and for those susceptible due to missed vaccination. Other areas of Spain implemented a different regimen in 2007, namely a 2-dose varicella vaccination for children aged 15 months and 3 years in Navarre. In Ceuta and Melilla, a 2-dose vaccination program was introduced in 2009 for children at 18 and 24 months and 15 and 24 months, respectively. The rest of the region introduced catch-up vaccinations for high-risk groups and children under 12 years of age [3,35]. Eventually, a universal varicella vaccination program for the whole country was adopted as a national immunization policy in 2016, and a 2-dose vaccination program was provided for children aged 15 months and 3 years [3].
Luxembourg began providing varicella vaccinations for high-risk groups in 2003 and introduced a 2-dose universal vaccination program for children aged 12 months and 15–23 months in 2009 [35]. It is the only European country that provides 2 doses of the MMRV vaccine.
Other countries, such as the United Kingdom (UK), have not introduced the varicella vaccine into their national immunization schedules because they consider varicella a mild disease and age shift as a burden of disease for the elderly including more severe complications and an increase in herpes zoster infection rates [25,37]. Moreover, some countries such as the UK and France have found that it is not cost-effective to adopt a universal varicella vaccination regimen [24].

3. American region

The United States was the first country to introduce a universal varicella vaccine regimen. In 1995, a 1-dose vaccination program was introduced at 12–15 months of age, while in 2006, the recommendation of a second dose for children 4–6 years of age was adopted. It has also been recommended that children, adolescents, and adults who were previously vaccinated receive a second dose [25].
Canada approved the varicella vaccine in December 1998; from 2000 to 2007, 13 regions introduced a universal vaccination program that provided a single dose at the age of 12–15 months [38]. However, breakthrough infections occur, and some patients are severely affected. This suggests that in a population vaccinated with only a single dose, immunity may wane over time, resulting in an increasing incidence among adolescents and adults, who may develop severe varicella symptoms and be prone to complications. In 2010, the National Advisory Committee on Immunization recommended a 2-dose varicella vaccine regimen [39]. As a result, a universal 2-dose vaccination program was implemented in 2011.
In 2016, the Latin American Society of Pediatric Infected Disorders recommended a national mandatory 2-dose varicella vaccine regimen in Latin America and the Caribbean. As of 2021, it has become a universal vaccination regimen in 15 countries, of which 7 provide 2 doses [40]. In other countries in the region, universal vaccination has not been introduced, but vaccinations are administered to high-risk groups. In Mexico, vaccinations are recommended for children in daycare facilities, immunodeficient patients, childhood cancer patients, and susceptible medical workers [41].

4. Eastern Mediterranean, African, and Southeast Asian regions

Six countries in the Middle East use a universal varicella vaccination program, and in all but Oman, a 2-dose schedule is implemented. Both Qatar and the United Arab Emirates have vaccine coverage rates exceeding 90% [42,43].
Three Southeast Asian countries (India, Indonesia, and Thailand) recommend varicella vaccination but have not added it to their NIP [44].
None of the other Southeast Asian or African countries have introduced a universal varicella vaccine regimen because of limited resources and the need to prioritize other vaccinated infectious diseases that create a much higher burden of disease on public health [45].

Varicella vaccine utilization in Korea

In Korea, a varicella vaccine was first licensed and distributed via the private market in 1988 [46]. Varicella became nationally notifiable in July 2005, when 1 dose of varicella vaccine was introduced to the NIP and recommended for children aged 12–15 months. Since it was designated a group 2 infectious disease in 2005, it has been included in the Korea Disease Control and Prevention Agency’s (KDCA) acute infectious disease annual monitoring report. Medical doctors, Oriental medical doctors, and heads of public health centers or commanders of the armed forces are required to immediately report a confirmed or probable case through a web-based reporting system.
According to the KDCA, 11,027 cases were reported in 2006 versus 20,284 in 2007, 44,450 in 2014, and 96,467 in 2018 [47]. Reported varicella cases slightly declined to 82,868 in 2019 and further decreased to 31,430 in 2020 due to coronavirus disease 2019 [48]. However, the Health Insurance Review and Assessment Service data from the National Health Insurance Service showed that the number of claims decreased during the period, with 194,283 cases in 2011, 101,861 cases in 2014, 86,465 cases in 2018, and 39,127 cases in 2020 [49]. Although these trends in varicella rates were inconsistent and involved their own bias, multiple studies assessing the effectiveness of varicella vaccine in Korea concluded insignificance of the varicella vaccine [19,50].
The number of vaccines approved for shipment in Korea ranged from 1,561,578 dozen (2012) to 4,695,282 dozen (2017) per year from 2011 to 2019, which is at least 3 to 10 times more than the 1-year birth cohort (Fig. 2). Meanwhile, the first vaccination rates for varicella vaccine exceeded 97% in 2015–2019, and it is assumed that the overshipped vaccines were used as secondary or catch-up doses because they were not counted in the statistics (Fig. 2).
Varicella is an important vaccine-preventable disease causing a significant burden not only in childhood but throughout the lifespan, resulting in shingles in the elderly population. The effectiveness of vaccination varies from 83% for the single dose to 95% for the 2 doses, which clearly shows the association between the number of doses and public health benefits [6]. We found an increased number of countries that included a 2-dose varicella vaccine regimen in the setting of expanding their program. The number of doses distributed annually does not accurately reflect the number of doses administered to children; therefore, our data require careful interpretation. Because the efficacy and effectiveness of vaccines and programs may vary among settings, vaccination strategies should be optimized for each country in the context of local epidemiology trends and health resources. Accordingly, the effectiveness of varicella vaccines requires separate evaluation under different conditions.


Real-world data on varicella vaccine effectiveness in Korea are currently limited. Previous studies demonstrated significant waning of immunity in those who received a 1-dose varicella vaccine [19,50]. For those who received 2-dose varicella vaccines, immunity waning has not yet been determined in a public program supporting a 1-dose vaccine strategy. Therefore, it is important to evaluate the effectiveness of the varicella vaccination program at the national level over a longer observation period to develop a data-driven policy to guide vaccination programs.


Conflicts of interest

No potential conflict of interest relevant to this article was reported.


This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contribution

Conceptualization: CYJ , KYK; Data curation: LYH, LJ, KE, LJY; Formal analysis: LYH, HK; Funding acquisition: KYK; Methodology: LYH, CYJ, KYK; Project administration: Lee J, Kim E, LJY; Visualization: LYH, CYJ; Writing - original draft: LYH, CYJ, KYK; Writing - review & editing: LYH, CYJ, KYK

Fig. 1.
World map showing the year of introduction of national varicella vaccination programs.
Fig. 2.
Annual varicella vaccine distribution and vaccination coverage, South Korea. Distribution is the number of vaccine doses distributed per year, while coverage rate is percentages of age-specific cohorts receiving vaccinations.
Table 1.
Licensed varicella vaccines
Strain of vaccine Manufacturer Trade name PFU/dose
 Oka/Merck MRC-5 Merck & Co. Inc., (United States) Varivax ≥1,350
 Oka GlaxoSmithKline (Belgium) Varilrix ≥2,000
 Oka/Biken Sanofi Pasteur (France) Okavax ≥1,000
 MAV/06 Green Cross (South Korea) SuduVax ≥1,400
 MAV/06 MRC-5 Green Cross (South Korea) BARTCELA ≥3,800
 Oka ChangChun Keygen Biological Products co., Ltd. (China) Vari-L ≥2,000
 Oka/SK MRC-5 SK Bioscience (South Korea) SKYvaricella ≥2,400
Measles, mumps, rubella, varicella
 Oka Merck & Co. Inc. (United States) ProQuad -
 Oka GSK (Belgium) Priorix-Tetra -

PFU, plague-forming units.

Table 2.
Recommended universal varicella vaccination programs of different countries
Country Vaccine Strain Dose 1st and 2nd dose introduction (yr) Schedule (1st, 2nd dose) Coverage (%)
Western Pacific 7 out of 27 member countries adopted (26%)
Australia Varicella, MMRV Oka 1 2005 18 mo 90% [30]
Hong Kong Varicella, MMRV Oka, MAV 2 2014 12 mo, 6 yr 73% [51]
Japan Varicella Oka 2 2014 12–15 mo, 18–23 mo 40% [32]
New Zealand Varicella Oka 1 2017 15 mo -
Niue Varicella - 1 2017 15 mo -
South Korea Varicella Oka, MAV 1 2005 12–15 mo 96.3% [17]
Taiwan Varicella Oka 1 2004 12–18 mo 98.6% [31]
Europe 14 out of 53 member countries adopted (26%)
Andorra Varicella Oka 2 No data 15 mo, 3 yr -
Austria Varicella Oka 2 2010 12–23 mo (4–wk interval) -
Cyprus Varicella Oka 2 2010 13–18 mo, 4–6 yr -
Finland Varicella, MMRV Oka 2 2017 18 mo, 6 yr -
Germany Varicella, MMRV Oka 2 2004, 2009 11–14 mo, 15–23 mo 1 dose 89.6% [52], 2 dose 75.3% [52]
Greece Varicella Oka 2 2006, 2009 12–15 mo, 2–3 yr 1 dose 90% [53], 2 dose 75% [53]
Hungary Varicella Oka 2 2019 13 mo, 16 mo -
Iceland Varicella Oka 2 2020 12 mo, 18 mo -
Israel Varicella, MMRV Oka 2 2008 12 mo, 6–7 yr -
12 m, 6 yr -
Italy Varicella, MMRV Oka 2 2017 13–15 mo, 6 yr 84%–95% [54]
Latvia Varicella Oka 2 2008, 2019 12–15 mo, 7 yr -
Luxembourg MMRV Oka 2 2009 12 mo, 15–23 mo 1 dose 94.5% [35], 2 dose 83.3% [35]
Spain Varicella Oka 2 2016 (National) 15 mo; 2–4 yr 4 regions
(Navarra) 15 mo; 3 yr 1 dose 95% [3], 2 dose 86.1% [3]
Turkey Varicella Oka 1 2013 12 mo 60.1% [43]
Americas 17 out of 35 member countries adopted (49%)
Antigua Varicella Oka, MAV 1 2014 24 mo -
Argentina Varicella Oka, MAV 1 2015 15 mo 74% [55]
Bahamas Varicella Oka, MAV 2 2012 12 mo, 4–5 yr -
Barbados Varicella Oka, MAV 1 2012 12 mo -
Bermuda Varicella Oka, MAV 1 2012 24 mo -
Brazil MMRV, Varicella Oka, MAV 2 2013, 2018 15 mo, 4 yr ≥80% [56]
Canada Varicella, MMRV Oka 2 2000–2007 (1 dose), 2011 (2 doses) 12-15 mo, 18 mo 93% [57]
Cayman Islands Varicella Oka, MAV 2 2000, 2009 12 mo, 3–6 yr -
Colombia Varicella Oka, MAV 2 2015, 2019 12 mo, 5 yr -
Costa Rica Varicella Oka, MAV 1 2007 15 mo 95% [58]
Ecuador Varicella Oka, MAV 1 2010 15 mo -
Panama Varicella Oka, MAV 2 2014, 2018 15 mo, 4 yr -
Paraguay Varicella Oka, MAV 1 2013 15 mo -
Peru Varicella Oka, MAV 1 2018 12 mo -
Puerto Rico Varicella Oka, MAV 2 1996, 2007 12 mo, 4–6 yr -
United States of America Varicella, MMRV Oka 2 1995, 2006 12–15 mo, 4–6 yr 90% [59]
Uruguay Varicella Oka, MAV 2 1999, 2014 12 mo, 5 yr 96% [60]
Eastern Mediterranean 6 out of 21 member countries adopted (29%)
Bahrain Varicella 2 2015 12 mo, 3 yr -
Kuwait Varicella, MMRV 2 2017 12 mo, 24 mo -
12–24 mo, 12 yr -
Oman Varicella 1 2010 12 mo -
Qatar Varicella Oka 2 2007 12 mo, 4–6 yr 92% [42]
Saudi Arabia Varicella 2 2008 18 mo, 4–6 yr -
United Arab Emirates Varicella 2 2012 12 mo, 5–6 yr 94% [43]

No African or Southeast Asian countries (47 and 11 members, respectively) have adopted universal varicella vaccination programs.


1. McDonald J. Vaccines for postexposure prophylaxis against varicella (chickenpox) in children and adults. Paediatr Child Health 2016;21:91–2.
crossref pmid pmc
2. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361–81.
crossref pmid pmc pdf
3. Spoulou V, Alain S, Gabutti G, Giaquinto C, Liese J, Martinon-Torres F, et al. Implementing universal varicella vaccination in Europe: the path forward. Pediatr Infect Dis J 2019;38:181–8.
4. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005;18:70–80.
crossref pmid pmc pdf
5. Varela FH, Pinto LA, Scotta MC. Global impact of varicella vaccination programs. Hum Vaccin Immunother 2019;15:645–7.
crossref pmid pmc
6. World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec 2014;89:265–87.
7. Choi EH. Varicella vaccination: worldwide status and previsional updated recommendation in Korea. Pediatr Infect Vaccine 2008;15:11–8.

8. Vázquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al. Effectiveness over time of varicella vaccine. JAMA 2004;291:851–5.
crossref pmid
9. Fu J, Wang J, Jiang C, Shi R, Ma T. Outbreak of varicella in a highly vaccinated preschool population. Intl J Infect Dis 2015;37:14–8.
10. Liese JG, Cohen C, Rack A, Pirzer K, Eber S, Blum M, et al. The effectiveness of varicella vaccination in children in Germany: a casecontrol study. Pediatr Infect Dis J 2013;32:998–1004.
11. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:955–60.
crossref pmid
12. Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002;347:1909–15.
crossref pmid
13. Zhu S, Zeng F, Xia L, He H, Zhang J. Incidence rate of breakthrough varicella observed in healthy children after 1 or 2 doses of varicella vaccine: results from a meta-analysis. Am J Infect Control 2018;46:e1–7.
crossref pmid
14. Spackova M, Wiese-Posselt M, Dehnert M, Matysiak-Klose D, Heininger U, Siedler A. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine 2010;28:686–91.
crossref pmid
15. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008;122:e744–51.
crossref pmid pdf
16. Marin M, Marti M, Kambhampati A, Jeram SM, Seward JF. Global varicella vaccine effectiveness: a meta-analysis. Pediatrics 2016;137:e20153741.
crossref pmid pdf
17. Jaeyoung L, Hangjin J, Seonju K, Jonghee K, Seonkui L. National childhood vaccination coverage among children aged 1-3 and 6 years in Korea, 2019. Cheongju (Korea): Korea Disease Control and Prevention Agency, 2020;:3549–59.

18. Lee YH, Choe YJ, Cho SI, Bang JH, Oh MD, Lee JK. Increasing varicella incidence rates among children in the Republic of Korea: an age–period– cohort analysis. Epidemiol Infect 2019;147:e245.
crossref pmid pmc
19. Lee YH, Choe YJ, Cho SI, Kang CR, Bang JH, Oh MD, et al. Effectiveness of varicella vaccination program in preventing laboratory-confirmed cases in children in Seoul, Korea. J Korean Med Sci 2016;31:1897–901.
crossref pmid pmc pdf
20. Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 2011;128:214–20.
crossref pmid pdf
21. Marshall HS, McIntyre P, Richmond P, Buttery JP, Royle JA, Gold MS, et al. Changes in patterns of hospitalized children with varicella and of associated varicella genotypes after introduction of varicella vaccine in Australia. Pediatr Infect Dis J 2013;32:530–7.
crossref pmid
22. Streng A, Grote V, Rack-Hoch A, Liese JG. Decline of neurologic varicella complications in children during the first seven years after introduction of universal varicella vaccination in Germany, 2005–2011. Pediatr Infect Dis J 2017;36:79–86.
crossref pmid
23. Wutzler P, Bonanni P, Burgess M, Gershon A, Sáfadi MA, Casabona G. Varicella vaccination-the global experience. Expert Rev Vaccines 2017;16:833–43.
crossref pmid pmc
24. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, et al. Varicella vaccination in Europe–taking the practical approach. BMC Med 2009;7:26.
crossref pmid pmc pdf
25. Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines 2014;2:39–55.
crossref pmid pmc pdf
26. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005;5:68.
crossref pmid pmc pdf
27. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288–90.
crossref pmid
28. Oh SH, Choi EH, Shin SH, Kim YK, Chang JK, Choi KM, et al. Varicella and varicella vaccination in South Korea. Clin Vaccine Immunol 2014;21:762–8.
crossref pmid pmc
29. Plotkin S, Orenstein W, Offit P, Edwards KM. Plotkin's vaccines. 7th ed. Philadelphia: Elsevier, 2017.

30. Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Org 2014;92:593–604.
crossref pmid pmc
32. Yoshikawa T, Kawamura Y, Ohashi M. Universal varicella vaccine immunization in Japan. Vaccine 2016;34:1965–70.
crossref pmid
33. Streng A, Grote V, Carr D, Hagemann C, Liese JG. Varicella routine vaccination and the effects on varicella epidemiology–results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011. BMC Infect Dis 2013;13:303.
crossref pmid pmc pdf
34. Vassiliki P, Konstantinos D, Myrsini M, Anna I, Maria T. Impact of routine varicella immunization on varicella ambulatory visits in a tertiary hospital in Athens, Greece. 2016. Clin Microbiol Infect Dis 2016;1:70–2.

35. Public health guidance on varicella vaccination in the European Union. Solna (Sweden): European Centre for Disease Prevention and Control, 2015.

36. D’Ancona F, D’Amario C, Maraglino F, Rezza G, Ricciardi W, Iannazzo S. Introduction of new and reinforcement of existing compulsory vaccinations in Italy: first evaluation of the impact on vaccination coverage in 2017. Eurosurveillance 2018;23:1800238.
pmid pmc
37. Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P. Modeling the impact of one-and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 2010;28:3385–97.
crossref pmid
38. Varicella (chickenpox) vaccine: Canadian immunization guide [Internet]. Government of Canada; [cited 2021 Sep 30]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/ canadian-immunization-guide-part-4-active-vaccines/page-24-varicellachickenpox-vaccine.html.

39. Salvadori M, Society CP, Diseases I, Committee I. Preventing varicella: recommendations for routine two-dose varicella immunization in children. Paediatr Child Health 2011;16:415–6.
crossref pmid pmc
40. Arlant LHF, Garcia MCP, Avila Aguero ML, Cashat M, Parellada CI, Wolfson LJ. Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review. BMC Public Health 2019;19:528.
crossref pmid pmc pdf
41. Ávila-Agüero ML, Beltrán S, Castillo JBD, Castillo Diaz ME, Chaparro LE, Deseda C, et al. Varicella epidemiology in Latin America and the Caribbean. Expert Rev Vaccines 2018;17:175–83.
42. Al-Turab M, Chehadeh W. Varicella infection in the Middle East: prevalence, complications, and vaccination. J Res Med Sci 2018;23:19.
crossref pmid pmc
43. Al Kaabi N, Al Olama FMAS, Al Qaseer M, Al Ubaidani I, Dinleyici EC, Hayajneh WA, et al. The clinical and economic burden of varicella in the Middle East: a systematic literature review. Hum Vaccin Immunother 2020;16:21–32.
crossref pmid pmc
44. Goh AEN, Choi EH, Chokephaibulkit K, Choudhury J, Kuter B, Lee PI, et al. Burden of varicella in the Asia-Pacific region: a systematic literature review. Expert Rev Vaccines 2019;18:475–93.
crossref pmid
45. Hussey HS, Abdullahi LH, Collins JE, Muloiwa R, Hussey GD, Kagina BM. Varicella zoster virus-associated morbidity and mortality in Africa: a systematic review protocol. BMJ Open 2016;6:e010213.
crossref pmid pmc
46. Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Sadao S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008;197:S185–90.
crossref pmid
47. Korea Disease Control and Prevention Agency. Infectious Disease Homepage [Internet]. Cheongju (Korea): Korea Disease Control and Prevention Agency; [updated 2011 Sep 30; cited 2021 Sep 30]. Available from: http://www.kdca.go.kr/npt/.

48. Yun HE, Ryu BY, Choe YJ. Impact of social distancing on incidence of vaccine-preventable diseases, South Korea. J Med Virol 2021;93:1814–6.
crossref pmid pdf
49. Health Insurance Review & Assessment Service. Healthcare Bigdata Hub [Internet]. Wonju (Korea): Health Insurance Review & Assessment Service; 2022 [updated 2021 Sep 30; cited 2021 Sep 30]. Available from: https://opendata.hira.or.kr/home.do.

50. Hong K, Sohn S, Choe YJ, Rhie K, Lee JK, Han MS, et al. Waning effectiveness of one-dose universal varicella vaccination in Korea, 2011– 2018: a propensity score matched national population Cohort. J Korean Med Sci 2021;36:e222.
crossref pmid pmc pdf
51. Chan D, Edmunds W, Chan H, Chan V, Lam Y, Thomas S, et al. The changing epidemiology of varicella and herpes zoster in Hong Kong before universal varicella vaccination in 2014. Epidemiol Infect 2018;146:723–34.
crossref pmid pmc
52. Rieck T, Feig M, An der Heiden M, Siedler A, Wichmann O. Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveill 2017;22:30521.
crossref pmid pmc
53. Panagiotopoulos T, Georgakopoulou T, Stavrou D, Danis K, Laggas D. National study of vaccination coverage among children, 2006. Athens: National School of Public Health, 2014.

54. Bechini A, Boccalini S, Baldo V, Cocchio S, Castiglia P, Gallo T, et al. Impact of universal vaccination against varicella in Italy: experiences from eight Italian regions. Hum Vaccin Immunother 2015;11:63–71.
55. Barrenechea GG, Bastos LS. Evaluation of impact of one dose varicella vaccine on the incidence of chickenpox in Argentina. Vaccine 2020;38:330–5.
crossref pmid
56. Vitale F, Amodio E. Evaluation of varicella vaccine effectiveness as public health tool for increasing scientific evidence and improving vaccination programs. J Pediatr (Rio J) 2020;96:670–2.
crossref pmid pmc
57. Hirose M, Gilio AE, Ferronato AE, Ragazzi SLB. The impact of varicella vaccination on varicella-related hospitalization rates: global data review. Rev Paul Pediatr 2016;34:359–66.
crossref pmid pmc
58. Avila-Aguero ML, Ulloa-Gutierrez R, Camacho-Badilla K, Soriano-Fallas A, Arroba-Tijerino R, Morice-Trejos A. Varicella prevention in Costa Rica: impact of a one-dose schedule universal vaccination. Expert Rev Vaccines 2017;16:229–34.
crossref pmid
59. Hill HA, Yankey D, Elam-Evans LD, Singleton JA, Pingali SC, Santibanez TA. Vaccination coverage by age 24 months among children born in 2016 and 2017—National Immunization Survey-Child, United States, 2017–2019. MMWR Morb Mortal Wkly Rep 2020;69:1505–11.
crossref pmid pmc
60. Quian J, Rüttimann R, Romero C, Dall’Orso P, Cerisola A, Breuer T, et al. Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997–2005. Arch Dis Child 2008;93:845–50.
crossref pmid pmc
METRICS Graph View
  • 13 Web of Science
  • 16 Crossref
  • 16 Scopus
  • 24,658 View
  • 341 Download